AdobeStock_337956230.jpeg
Background.png

YOUR WEEKLY

CLINICAL CONVERSATIONS

FOR PHARMACISTS

EPISODE

2

The evidence for SGLT2 drugs for heart failure in patients without diabetes

Emerging evidence suggests that patients with COVID infection may be hypercoagulable and prone to clotting. Listen in as we discuss the evidence surrounding this issue and how to address therapeutic issues in anticoagulation in this population.

 

This episode is accredited for CPE.  For CE details and to claim credit:

  1. Click here to claim your credit (learn.ceimpact.com/login)

  2. Enter Code GC203 on the homepage + hit submit

  3. Click on the course title in you My Courses to complete the exam and evaluation

EPISODE

1

Hypercoagulability with COVID-19 infection

SGLT2 inhibitors, also called gliflozins, are a class of medications that inhibit reabsorption of glucose in the kidney and therefore lower blood sugar.  Recently SGLTs, which are currently indicated for Type 2 diabetes have been investigated and received FDA approval for Heart failure with reduced ejection fraction (HFrEF).  Listen in to this episode to discover more about how these drugs work in this (HFrEF) disease state.

 

This episode is accredited for CPE.  For CE details and to claim credit:

  1. Click here to claim your credit (learn.ceimpact.com/login)

  2. Enter Code GC202 on the homepage + hit submit

  3. Click on the course title in you My Courses to complete the exam and evaluation

Proud to be a partner with Pharmacy Podcast Network

©2019 CEImpact

  • Grey LinkedIn Icon
  • Grey Facebook Icon
  • Grey Instagram Icon
  • Grey Twitter Icon